Remembering Dr. Craig Leonardi
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.
IPC Councilor José-Manuel Carrascosa Carrillo, MD, PhD, on the BeNeBio trial and whether dose reduction fits an era focused on disease modification.
What happened in psoriasis at the 2026 EADV Congress? IPC shares highlights from its symposium on personalized medicine, as well as psoriasis sessions and late-breaking research from Vienna.
World Psoriasis Day, observed each year on October 29, was launched by the International Federation of Psoriasis Associations (IFPA) in 2004 to give a voice to the more than 125 million people worldwide living with psoriasis and psoriatic arthritis. To mark this year’s observance, IPC joined the Latin American Society of Psoriasis and Dermoimmunology (SOLAPSO) and the Skin Inflammation and Psoriasis International Network (SPIN) to create a video series around the theme “Look Beyond My Skin,” featuring voices from all three organizations. Missed the videos on social media? Watch the full series on the IPC YouTube channel.
Take Two with IPC gives a longer presentation a second life in two minutes. Each video takes an expert talk IPC has already published (a Take Ten recording or a symposium presentation) and condenses the clinical substance. The series launched this month alongside the World Psoriasis Day campaign with four videos on pediatric psoriasis: Psoriasis Look-Alikes and Anti-TNF-α Induced Skin Eruptions with IPC Board Member Amy Paller, MS, MD; Conventional Therapies with IPC Councilor Mona El-Kalioby, MBBCh, MSc, MD; and Phototherapy in Pediatric Psoriasis with Fernando Valenzuela, MD. New Take Two videos will be featured each month, drawn from the Take Ten with IPC library and recordings from IPC symposia, with a link to the full presentation for each.
Select presentations from the Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum, hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the 55th Annual European Society for Dermatological Research (ESDR) Meeting, are now available. Topics include disease endotypes, atopic dermatitis-psoriasis overlap, cardiovascular risk in psoriasis, and genetic susceptibility.
In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in psoriasis, why these distinctions matter, what current research tells us, and which areas should be prioritized in future psoriasis research.
First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study
Matías Maskin, MD
CEMIC University, at Buenos Aires
Buenos Aires, Argentina
IPC Councilor
PUBLICATION
Using Biologic Therapies as First-Line Systemic Treatment for Psoriasis: A Cohort Study Following the Target Trial Emulation Framework from the Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Phan DB, Laws P, Smith CH, et al. Br J Dermatol. 2026. doi: 10.1093/bjd/ljag098
Why This Article Was Chosen
This article was selected because it examines whether biologic therapies should be used as first-line systemic treatment in psoriasis. Using data from the Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), Phan DB and colleagues show improved clinical outcomes, faster skin clearance, and a lower risk of comorbidities with early biologic use. These findings challenge step-up approaches that delay access to effective therapies due to cost and add growing evidence supporting earlier treatment strategies in psoriasis care.
Commentary
Psoriasis is a chronic inflammatory disease that can alter an individual’s life course, causing physical and emotional effects and reducing quality of life. It is associated with cardiovascular comorbidities and increased cardiovascular mortality and is related to other comorbidities such as inflammatory bowel disease, malignancy, obesity, and mood disorders. 1
Moderate to severe psoriasis is usually treated with systemic therapies, but most guidelines suggest starting treatment with conventional systemic drugs. Biologic therapies that are more effective, safer, and faster to improve patients’ outcomes are frequently considered second-line options solely because of cost. 2,3 The appearance of biosimilar therapies has improved access to biologic therapy by lowering the cost of psoriasis treatment. Some authors have also demonstrated faster responses with biologics as first-line treatments, proposing a step-down rather than a step-up approach. 4
The study published by Phan and colleagues is a cohort study that follows the target trial emulation framework and uses data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). This registry includes patients treated with biologic and non-biologic systemic therapies for psoriasis since 2007. The emulated trial was a randomized, open-label study of adults (≥18 years) with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index 10 [PASI] ≥10), comparing first-line biologic therapy with first-line conventional systemic therapies (methotrexate, ciclosporin, or acitretin).
The primary outcome was the change in PASI over 5 years of follow-up, and the secondary outcomes were time to first achievement of complete skin clearance (PASI = 0), change in the Dermatology Life Quality Index (DLQI), and time to first newly diagnosed chronic comorbidities. They fitted pooled weighted logistic regression models, which approximate the discrete-time hazard ratio, to estimate time-to-event outcomes: (i) achieving complete skin clearance (PASI = 0), and (ii) development of chronic comorbidities. The study included 3,702 patients: 3,368 received standard of care, and 334 initiated a biologic as their first-line systemic treatment.
The patients starting with a biologic were older, had more comorbidities, and were more likely to have psoriatic arthritis. They also had longer disease duration and higher PASI. The first treatment change occurred earlier in patients receiving standard of care than in those receiving biologics (13.3 months vs 19.9 months). Patients starting first-line biologic therapy had lower PASI at 1 (2.4 vs 6.7) and 5 (2.0 vs 4.7) years, and lower DLQI at 1 (4.0 vs 7.9) and 5 (3.5 vs 5.3) years, and had a lower risk of developing new chronic comorbidities over five years. The rate of achieving PASI 0 was 58.6% in patients starting biologics, compared with 32.1% in patients following conventional treatment, and the mean time to PASI 0 was 13.3 months in patients receiving first-line biologics vs 23.3 months in patients receiving standard-of-care treatment.
Patients with moderate to severe psoriasis often require multiple treatment options with slow onset of action and lower efficacy, resulting in cumulative waiting times to clear psoriasis.5 Delaying effective treatment promotes cumulative life impairment, the development of comorbidities, and unhealthy behaviors like smoking and alcohol consumption. Rapid and almost clearance responses have been identified as a crucial outcome for patients.6
On the other hand, there is growing evidence that early intervention with highly effective treatments may reduce the incidence of comorbidities, lower long-term disease burden, and improve disease control7. Treatment sequences that start with nonbiological agents appear to be associated with lower time-effectiveness ratios. In contrast, initiating biologics as first-line systemic treatment for moderate to severe psoriasis is associated with greater clinical improvement, higher rates of complete skin clearance, and a lower risk of chronic comorbidities over five years, compared with the current standard-of-care approach. Patients who start with conventional treatments often experience longer periods of suboptimal disease control, undergo more frequent switching and cycling, and face delays in achieving standard therapeutic targets.8
This emerging evidence supports improving access to biologics as first-line treatment and exploring alternative cost-reduction strategies, such as dose de-escalation once therapeutic goals have been achieved. 9
References
Categories
Recent Posts
FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement on Tuberculosis Testing
Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?
Remembering Dr. Craig Leonardi
Also Read
Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?
IPC Councilor José-Manuel Carrascosa Carrillo, MD, PhD, on the BeNeBio trial and whether dose reduction fits an era focused on disease modification.
Highlights from the 2026 European Academy of Dermatology and Venereology (EADV) Congress: Personalized Medicine, Therapeutic Advances, and Late-Breaking Research
What happened in psoriasis at the 2026 EADV Congress? IPC shares highlights from its symposium on personalized medicine, as well as psoriasis sessions and late-breaking research from Vienna.
When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most
Can a psoriasis patient with cancer still receive biologic therapy? IPC’s newest manuscript gives dermatologists and oncologists a shared, evidence-based answer, including which therapies to favor, which to avoid, and why the two specialties need to decide together.
Subscribe to the IPC Newsletter